University of Maryland, Baltimore and MedImmune are pairing up for a five-year, $6 million collaboration on bioscience research.
The Gaithersburg-based drug company and the university will both put money and scientists toward joint research projects. The projects will focus on medical conditions and diseases in MedImmune’s wheelhouse, such as cardiovascular disease, respiratory problems and inflammation.